Psyence Group

Home » Archives for Psyence Group

About Psyence Group

This author has not yet filled in any details.
So far Psyence Group has created 64 blog entries.
  • Newcourt to Acquire Psyence’s Clinical Trials Division

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

2023-01-10T10:20:30+02:00January 10, 2023|Press Releases, Investor Information|

Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

2022-11-29T19:40:20+02:00November 29, 2022|Press Releases, Investor Information, Psychedelic News|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Go to Top